CCO Treatment Updates

Treatment Challenges in Myelodysplastic Syndromes

Module

Insights Into the Pathogenesis, Classification, and Treatment of Myelodysplastic Syndromes

Faculty:
Alan F. List, MD

CME CREDIT INFORMATION

Release Date: 04/02/08

Expiration Date: 04/01/09

Physicians: maximum of 1.25 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.2 Nursing CE credits

Status: Please log in to view status

Alan F. List, MD, reviews current clinical trial data regarding the clinical management of patients with MDS.

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the various classification systems for myelodysplastic syndromes
Discuss data from clinical studies of approved and investigational treatments for myelodysplastic syndromes
Explain the underlying pathogenesis of myelodysplastic syndromes

Interactive Case Challenges

Clinical Management of a 69-Year-Old Man With Intermediate-1-Risk Myelodysplastic Syndrome

Faculty:
Azra Raza, MD Naomi Galili, PhD

CME CREDIT INFORMATION

Release Date: 04/08/08

Expiration Date: 04/07/09

Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Registered Nurses: 0.8 Nursing CE credit

Status: Please log in to view status

In this Interactive Case Challenge, Azra Raza, MD, and Naomi Galili, PhD, discuss treatment options for a patient with intermediate-risk myelodysplastic syndrome and monosomy of chromosome 7.

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss recent data from clinical studies of approved and investigational treatments for myelodysplastic syndromes
Summarize optimal clinical management strategies for patients with intermediate-1–risk myelodysplastic syndromes and cytogenetic abnormalities
Explain the differences between azacitidine and decitabine in the treatment of myelodysplastic syndromes
Describe the use of erythropoiesis-stimulating agents in the treatment of myelodysplastic syndromes

Management of a 69-Year-Old Patient With Deletion 5q Myelodysplastic Syndrome

Faculty:
Alan F. List, MD

CME CREDIT INFORMATION

Release Date: 04/09/08

Expiration Date: 04/08/09

Physicians: maximum of 0.5 AMA PRA Category 1 Credit(s)™

Registered Nurses: 0.7 Nursing CE credit

Status: Please log in to view status

Alan F. List, MD, reviews treatment options for a patient with del(5q) MDS.

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize initial treatment options for patients with newly diagnosed low-risk myelodysplastic syndromes
Describe the appropriate use of erythropoiesis-stimulating agents in the treatment of patients with myelodysplastic syndromes
Discuss recent data from clinical studies of azacitidine and decitabine for myelodysplastic syndromes
Define the settings in which lenalidomide would be used to treat myelodysplastic syndromes

Treatment of a 52-Year-Old Man With High-Risk Myelodysplastic Syndrome

Faculty:
Charles A. Schiffer, MD

CME CREDIT INFORMATION

Release Date: 06/03/08

Expiration Date: 06/02/09

Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Registered Nurses: 0.7 Nursing CE credit

Status: Please log in to view status

Charles A. Schiffer, MD, presents treatment options for a patient with newly diagnosed high-risk myelodysplastic syndrome

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the features of high-risk myelodysplastic syndrome
Relate the first-line treatment options for high-risk myelodysplastic syndrome
Describe the factors to consider in allogeneic stem cell transplantation in myelodysplastic syndrome
Explain the use of hypomethylating agents in high-risk myelodysplastic syndrome

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.